title: Safety and efficacy of low-dose pre-phase before conventional-dose chemotherapy for ulcerative gastric diffuse large B-cell lymphoma.
abstract: Potentially fatal chemotherapy (CT)-related gastrorrhagia and gastric perforation in patients with gastric lymphoma present difficult problems to doctors. We retrospectively analyzed 54 patients with ulcerative gastric diffuse large B-cell lymphoma (G-DLBCL) to compare the safety and efficacy of low-dose pre-phase CT before 4-6 cycles of conventional-dose CT (n = 28) with 4-6 cycles of conventional-dose CT (n = 26) between October 2005 and August 2014. Patients who received low-dose pre-phase before conventional-dose CT showed a lower gastrorrhagia or gastric perforation rate (0% vs. 15.4%, p = 0.047) and higher complete response (CR) rate (78.6% vs. 46.2%, p = 0.023) and 5-year progression-free survival (PFS) rate (63% vs. 31%, p = 0.021) than patients who received conventional-dose CT alone. Our study suggests that low-dose pre-phase therapy before conventional-dose CT provides a safe and effective method for ulcerative G-DLBCL.
authors: a Department of Oncology , The First Affiliated Hospital of Zhengzhou University , Zhengzhou , Henan , China.
authors: Yingying
authors: Y
authors: Cui
authors: a Department of Oncology , The First Affiliated Hospital of Zhengzhou University , Zhengzhou , Henan , China.
authors: Xin
authors: X
authors: Li
authors: a Department of Oncology , The First Affiliated Hospital of Zhengzhou University , Zhengzhou , Henan , China.
authors: Zhenchang
authors: Z
authors: Sun
authors: b The Affiliated Cancer Hospital of Zhengzhou University , Zhengzhou , Henan , China.
authors: Changsen
authors: C
authors: Leng
authors: c Department of Hematopathology , The University of Texas M. D. Anderson Cancer Center , Houston , TX , USA.
authors: Ken
authors: K
authors: Young
authors: a Department of Oncology , The First Affiliated Hospital of Zhengzhou University , Zhengzhou , Henan , China.
authors: Xiaolong
authors: X
authors: Wu
authors: a Department of Oncology , The First Affiliated Hospital of Zhengzhou University , Zhengzhou , Henan , China.
authors: Lei
authors: L
authors: Zhang
authors: a Department of Oncology , The First Affiliated Hospital of Zhengzhou University , Zhengzhou , Henan , China.
authors: Xiaorui
authors: X
authors: Fu
authors: a Department of Oncology , The First Affiliated Hospital of Zhengzhou University , Zhengzhou , Henan , China.
authors: Ling
authors: L
authors: Li
authors: a Department of Oncology , The First Affiliated Hospital of Zhengzhou University , Zhengzhou , Henan , China.
authors: Xudong
authors: X
authors: Zhang
authors: a Department of Oncology , The First Affiliated Hospital of Zhengzhou University , Zhengzhou , Henan , China.
authors: Yu
authors: Y
authors: Chang
authors: a Department of Oncology , The First Affiliated Hospital of Zhengzhou University , Zhengzhou , Henan , China.
authors: Feifei
authors: F
authors: Nan
authors: a Department of Oncology , The First Affiliated Hospital of Zhengzhou University , Zhengzhou , Henan , China.
authors: Zhaoming
authors: Z
authors: Li
authors: a Department of Oncology , The First Affiliated Hospital of Zhengzhou University , Zhengzhou , Henan , China.
authors: Jiaqin
authors: J
authors: Yan
authors: a Department of Oncology , The First Affiliated Hospital of Zhengzhou University , Zhengzhou , Henan , China.
authors: Zhiyuan
authors: Z
authors: Zhou
authors: a Department of Oncology , The First Affiliated Hospital of Zhengzhou University , Zhengzhou , Henan , China.
authors: Mingzhi
authors: M
authors: Zhang
authors: d Department of Pathology , The First Affiliated Hospital of Zhengzhou University , Zhengzhou , Henan , China.
authors: Wencai
authors: W
authors: Li
authors: d Department of Pathology , The First Affiliated Hospital of Zhengzhou University , Zhengzhou , Henan , China.
authors: Guannan
authors: G
authors: Wang
authors: d Department of Pathology , The First Affiliated Hospital of Zhengzhou University , Zhengzhou , Henan , China.
authors: Dandan
authors: D
authors: Zhang
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D003520:Cyclophosphamide / Q000008:administration & dosage; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D005260:Female; D006801:Humans; D007970:Leukopenia / Q000139:chemically induced; D016403:Lymphoma, Large B-Cell, Diffuse / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D009503:Neutropenia / Q000139:chemically induced; D012074:Remission Induction; D012189:Retrospective Studies; D013274:Stomach Neoplasms / Q000188:drug therapy*; D013276:Stomach Ulcer / Q000188:drug therapy*; D016896:Treatment Outcome; D014750:Vincristine / Q000008:administration & dosage; D055815:Young Adult
chemical_list: D014750:Vincristine; D003520:Cyclophosphamide
keywords: Chemotherapy; complication; gastric lymphoma; ulcer